Dimeric NGF Mimetic Attenuates Hyperglycaemia and DNA Damage in Mice with Streptozotocin-induced Early-stage Diabetes.
NGF deficiency is one of the reasons for reduced β-cells survival in diabetes. Our previous experiments revealed the ability of low-weight NGF mimetic, GK-2, to reduce hyperglycaemia in a model of advanced diabetes. The increase in DNA damage in advanced diabetes was repeatedly reported, while there were no data about DNA damage in initial diabetes. Establish whether DNA damage occurs already in initial diabetes and whether GK-2 is able to overcome them. The early-stage diabetes was modelled in Balb/c mice by streptozotocin (STZ) (130 mg/kg, i.p.). GK-2 was administered at a dose of 0.5 mg/kg, i.p., chronically. The evaluation of DNA damage was performed using the alkaline comet assay; the percentage of DNA in the tail (%TDNA) and the percentage of the atypical DNA comets ("ghost cells") were determined. STZ at this subthreshold dose produced a slight increase in glycemia and MDA. Meanwhile, pronounced DNA damage was observed, concerning mostly the percentage of "ghost cells" in pancreas, liver and kidneys. GK-2 attenuated the degree of hyperglycaemia and reduced the % of "ghost cells" and %TDNA in all organs examined; this effect continued after therapy discontinuation. Early-stage diabetes is accompanied by DNA damage, manifested themselves in the increase of "ghost cells" percentage. The severity of these changes significantly exceeds the degree of hyperglycaemia and MDA accumulation. GK-2 exerts an antihyperglycaemic effect and attenuates the degree of DNA damage. Our results indicate that the comet assay is a highly informative method for the antidiabetic medicines searching.